Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
930.76
-1.30 (-0.14%)
Streaming Delayed Price
Updated: 12:21 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Eli Lilly Slashes Zepbound Weight Loss Vial Prices By Up To 50% To Boost Access
August 27, 2024
Eli Lilly launches low-dose Zepbound vials for weight loss, offering 2.5 mg and 5 mg options for self-pay patients. These vials, priced at a significant discount compared to other GLP-1 obesity drugs,...
Via
Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
August 27, 2024
The single-dose vials will also increase supply, the drug giant says.
Via
Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
August 27, 2024
Shareholders don't have too much to fear -- yet.
Via
The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
August 26, 2024
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...
Via
Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
August 26, 2024
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Via
MarketBeat
Exploring The Competitive Space: Eli Lilly Versus Industry Peers In Pharmaceuticals
August 23, 2024
Via
Benzinga
Check Out What Whales Are Doing With LLY
August 22, 2024
Via
Benzinga
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety
August 26, 2024
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed.
Via
Benzinga
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
August 26, 2024
The new drugs this company is developing could be worth a lot more than the present market value of its stock.
Via
The Motley Fool
Mounjaro Scores Yet Another Win: Why Eli Lilly Is Still a Buy
August 25, 2024
The drugmaker looks unstoppable.
Via
The Motley Fool
If You Like Eli Lilly, Then You'll Love This Little-Known Specialty Manufacturing Stock
August 24, 2024
Jacobs Solutions stands to be a beneficiary of the red-hot weight loss movement fueling the pharmaceutical market.
Via
The Motley Fool
Prediction: These Will Be the Best-Performing S&P 500 Stocks of 2024
August 24, 2024
The S&P 500's top three at year-end could look a little different than they do now.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
AskSlim Market Week - Friday, Aug. 23
August 23, 2024
An analysis and commentary on the financial markets.
Via
Talk Markets
Why Apple Stock And This 'Recession-Proof' Leader Strengthen Market's Bull Case
August 23, 2024
What happens when you get rate cuts as a tech revolution is starting? An environment that's set to supercharge the stock market, says this expert.
Via
Investor's Business Daily
Stock Market Rallies As Powell Confirms Rate Cuts; Palo Alto, Cava, Target Jump: Weekly Review
August 23, 2024
Palo Alto and Cava were among the earnings winners.
Via
Investor's Business Daily
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
August 23, 2024
Kellanova and Fortinet are leading the S&P 500's August performance.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Visualizing The World’s Top 25 Companies By Market Cap
August 23, 2024
The world’s top 25 companies by market capitalization.
Via
Talk Markets
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
August 23, 2024
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
Via
News Direct
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
August 23, 2024
Ozempic remains on top in the GLP-1 drug market -- but for how long?
Via
The Motley Fool
Eli Lilly Hits All-Time High, Gets Watchlist Trifecta: These Names Just Added To IBD 50, Other Top Stock Screens
August 22, 2024
Eli Lilly deserved landing on three top stock lists. The drug giant hit an all-time high Thursday and has surging earnings and revenue.
Via
Investor's Business Daily
Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better
August 22, 2024
Eli Lilly's valuation may seem high right now, but with fast earnings growth, today's price could look like a deal in a few years.
Via
The Motley Fool
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
August 22, 2024
This leading pharmaceutical stock is flying under the radar right now.
Via
The Motley Fool
Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
August 21, 2024
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provides a $249 monthly alternative to expensive obesity treatments.
Via
Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
August 21, 2024
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish...
Via
Benzinga
Topics
Economy
Exposures
Supply Chain
Asia Mixed, European Markets Advance; Gold Stays Near All Time High While Dollar Gains - Global Markets Today While US Slept
August 21, 2024
US stock markets close lower, breaking 8-day winning streak as investors pause before economic symposium. Energy stocks decline, consumer staples gain.
Via
Benzinga
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
August 21, 2024
The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run.
Via
The Motley Fool
Why Eli Lilly Topped the Market on Tuesday
August 20, 2024
The company had very encouraging news to report about its hottest product.
Via
The Motley Fool
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Wall Street Eases, Bonds Rises, US Dollar Falls To 8-Month Low: What's Driving Markets Tuesday?
August 20, 2024
It’s a relatively uneventful session on Wall Street, but with a slightly worsening risk sentiment as all U.S. equity indices traded in the red at around midday trading in New York.
Via
Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
August 20, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.